Safety & Efficacy of RX-af01 Combined With PD-1 Antibody

Status Recruiting

Clinical Trial Summary

This phase I trial evaluates the effects of RX-af01 in combination with toripalimab (PD-1 antibody), in treating patients with refractory advanced solid tumors, including melanoma, nasopharyngeal squamous carcinoma, esophageal squamous cell carcinoma, gastric adenocarcinoma, renal cell carcinoma, et al. RX-af01 is a kind of anti-tumor intestinal bacteria developed by our research group. Its main components are symbiotic bacteria from human intestine - Alisipes finegoldii (A. finegoldii.), which is a Gram negative anaerobic bacteria. Our previous research shows that A finegoldii. can significantly enhance the anti-tumor activity of PD-1 antibody in multiple mouse tumor models. Mechanism research shows that A finegoldii. can increase the infiltration of CD4 and CD8 positive immune cells in the tumor microenvironment, and enhances the anti-tumor activity of immune cells. The primary aim of this study is to explore the efficacy and safety of RX-af01 combined with PD-1 antibody in refractory advanced solid tumors.

Clinical Trial Description

This is a phase Ib study to evaluate the effects of RX-af01 in combination with toripalimab (PD-1 antibody), in treating patients with refractory advanced solid tumors, including melanoma, nasopharyngeal squamous carcinoma, esophageal squamous cell carcinoma, gastric adenocarcinoma, renal cell carcinoma, et al. This study will include 3 chorts. Cohort 1 uses the regular dose of RX-af01. Cohort 2 uses a high dose of RX-af01 which is 5 times of the regular dose of RX-af01. Cohort 3 uses a mixed bacteria including RX-af01, Bifidobacterium longum RX02 and Ligilactobacillus salivarius RX02. Primary endpoint: To determine the safety and efficacy of bacterial strain RX-af01 in combination with toripalimab in refractory advanced solid tumors. Secondary endpoint: 1. Progression free survival (PFS) 2. Overall survival (OS) 3. Duration of response (DOR) 4. Tumor microenvironment 5. Changes in flora species/abundance ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05576961
Study type	Interventional
Source	Sun Yat-sen University
Contact	Miao-Zhen Qiu
Phone	+862087343351
Email	qiumzh@sysucc.org.cn
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	September 15, 2022
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05580991` - Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors	Phase 1
Recruiting	`NCT05691608` - MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2	N/A
Active, not recruiting	`NCT02846038` - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Recruiting	`NCT05159388` - A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors	Phase 1/Phase 2
Completed	`NCT03181854` - Randomized Controlled Trial of Integrated Early Palliative Care	N/A
Recruiting	`NCT06014502` - Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors	Phase 1
Recruiting	`NCT05981703` - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors	Phase 1
Recruiting	`NCT04107311` - Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
Active, not recruiting	`NCT04078152` - Durvalumab Long-Term Safety and Efficacy Study	Phase 4
Completed	`NCT02250157` - A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies	Phase 1
Recruiting	`NCT05566574` - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer	Phase 1/Phase 2
Recruiting	`NCT03943004` - Trial of DFP-14927 in Advanced Solid Tumors	Phase 1
Recruiting	`NCT06036836` - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)	Phase 2
Recruiting	`NCT05525858` - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Recruiting	`NCT05798546` - Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)	Phase 1
Terminated	`NCT04586335` - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.	Phase 1
Active, not recruiting	`NCT00479128` - Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors	Phase 1
Recruiting	`NCT04143789` - Evaluation of AP-002 in Patients With Solid Tumors	Phase 1/Phase 2
Not yet recruiting	`NCT04550663` - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors	Phase 1
Completed	`NCT03980041` - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Safety and Efficacy of RX-af01 Combined With PD-1 Antibody

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms